期刊文献+

阿折地平对自发性高血压大鼠左心室肥厚的抑制作用 被引量:1

Inhibitory effect of Azelnidipin on left ventricular hypertrophy in spontaneous hypertension rats
原文传递
导出
摘要 目的观察阿折地平对自发性高血压大鼠(spontaneous hypertension rat,SHR)心肌肥厚的抑制作用,初步探讨阿折地平抑制和逆转左心室肥厚(left ventricular hypertrophy,LVH)的可能机制。方法 20只SHR随机分为阿折地平组和SHR组,另选同源同系、血压正常的Wistar-Kyoto大鼠10只作为正常对照组(WKY组),分别给予阿折地平(3mg.kg-1)和生理盐水灌胃,所有大鼠10周后测定收缩压(SBP)、心率(HR)、左心室重量指数(LVW/BW)、血清和心肌组织中一氧化氮(NO)和肿瘤坏死因子(TNF-α)含量。结果 SHR组与WKY组比较,SHR组SBP、LVW/BW明显升高(P<0.05),血清和心肌中NO含量明显降低(P<0.05),TNF-α含量明显升高(P<0.05);应用阿折地平治疗10周后,SHR组与阿折地平组比较,阿折地平组SBP、LVW/BW有所升高(P<0.05),血清和心肌中NO含量明显升高(P<0.05),TNF-α含量明显降低(P<0.05)。结论阿折地平可以抑制高血压大鼠心肌肥厚,机制可能与其升高NO水平,抑制TNF-α表达有关。 Objective To explore the inhibitory effect of Azelnidipin on left ventricular hypertrophy in spontaneous hypertension rats(SHRs).Methods Twenty healthy SHRs were randomLy divided into the Azelnipin treatment group and the SHR group.At the same time,ten WKY rats(the WKY group) served as the normal control group.Rats in the Azelnidipin group were treated with Azelnidipin for 10 weeks and rats in the SHR and WKY groups were treated with 0.9% NaCl of the same volume.Ten weeks later,SBP,HR and the indexes of LVW/BW,TNF-α and NO were determined.Results Compared with the WKY group,SBP,LVW/BW and TNF-α of the SHR groups had a great increase(P0.05),and NO in the serum and myocardium decreased(P0.05).Compared with the SHR group,SBP,LVW/BW and NO in the serum and myocardium of the Azelnidipin group significantly increased(P0.05),while TNF-αdecreased(P0.05).Conclusion Azelnipin may inhibit left ventricular hypertrophy of SHR,which may be related to the increase of NO and decrease of TNF-α.
出处 《山东大学学报(医学版)》 CAS 北大核心 2010年第8期28-31,共4页 Journal of Shandong University:Health Sciences
关键词 阿折地平 自发性高血压 大鼠 肿瘤坏死因子 Azelnipin Spontaneous hypertension Rats Tumor necrosis factor-alpha
  • 相关文献

参考文献14

二级参考文献77

共引文献65

同被引文献14

  • 1Wellington K,Scott LJ. Azelnidipine[J].{H}DRUGS,2003,(23):2613-2621.
  • 2Mitsuyoshi K,Kiyoshi K,Kunihiro S. Phase I Study of CS-905, a New Calcium Antagonist. II. A Single Dose Study on Healthy Volunteers:Influence of Food Intake[J].Rinsho lyaku,2000,(02):179.
  • 3Jinno T,Iwai M,Li Z. Calcium Channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan[J].{H}HYPERTENSION,2004,(02):263-269.
  • 4ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group,The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin vs usual care:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT-LLT)[J].{H}JAMA:the Journal of the American Medical Association,2002,(23):2998-3007.
  • 5Julius S,Kjeldsen SE,Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[J].{H}LANCET,2004,(9426):2022-2031.
  • 6Dahl?f B,Sever PS,Poulter NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required,in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA):a multicentre randomised controlled trial[J].{H}LANCET,2005,(9489):895-906.
  • 7Arita M,Hashizume T,Tanigawa K. A new Ca-antagonist,azelnidipine,reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension:a randomized,double-blind,placebo-controlled trial[J].{H}Journal of Cardiovascular Pharmacology,1999,(02):186-192.
  • 8Yoshinaga K,Iimura O,Abe K. Late phase II study of CS-905,azelnidipine,in patients with essential hypertension:a multi-center,double-blind comparative study for evaluation of optimal dose[J].Rinsho Iyaku,1999,(06):907.
  • 9Kuramoto K,Ichikawa S,Hirai A. Azelnidipine and amlodipine:a comparison of their pharmacokinetics and effects on ambulatory blood pressure[J].{H}Hypertension Research,2003,(03):201-208.
  • 10Yoshinaga K,Iimur O,Abe K. A multicenter doubleblind comparison study of CS-905(azelnidipine)with nitrendipine in patients with essential hypertension[J].Rinsho lyaku,2000,(05):671.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部